See more : Mex Polska S.A. (MEX.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Enanta Pharmaceuticals, Inc. (ENTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enanta Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pricer AB (publ) (PCRBF) Income Statement Analysis – Financial Results
- Index Oil and Gas Inc. (IXOG) Income Statement Analysis – Financial Results
- HBM Holdings Limited (HBMHF) Income Statement Analysis – Financial Results
- Waterco Limited (WAT.AX) Income Statement Analysis – Financial Results
- Spencer’s Retail Limited (SPENCERS.NS) Income Statement Analysis – Financial Results
Enanta Pharmaceuticals, Inc. (ENTA)
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
Cost of Revenue | 0.00 | 0.00 | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 67.64M | 79.20M | 83.19M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
Gross Profit Ratio | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
General & Administrative | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 0.00 | 6.11M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 5.04M | 6.11M |
Other Expenses | 0.00 | 0.00 | 83.00K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 0.00 | 5.04M | 309.00K |
Operating Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
Cost & Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | 0.00 | 2.53M | 1.74M | 968.00K | 467.00K | 248.00K | 118.00K | 83.00K | 14.00K |
Interest Expense | 10.94M | 5.15M | 1.57M | 0.00 | 0.00 | 8.82M | 4.85M | 40.00K | 45.00K | 8.00K | 18.00K | 31.00K | 0.00 | 3.16M | 0.00 |
Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639.00K | 352.00K | 221.00K | 172.00K | 499.00K | 553.00K |
EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -38.00M | 40.00M | 90.85M | 26.75M | 32.50M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.30M |
EBITDA Ratio | -154.52% | -155.90% | -140.38% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.74% | 61.80% | 34.35% |
Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.99M | 9.03M | 21.29M | 25.30M | 6.94M |
Operating Income Ratio | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% | 30.50% |
Total Other Income/Expenses | 3.90M | 6.21M | 1.66M | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 110.00K | -1.99M | 805.00K |
Income Before Tax | -117.79M | -131.00M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.46M | 19.27M | 9.63M | 21.40M | 23.31M | 7.75M |
Income Before Tax Ratio | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% | 22.20% | 45.07% | 26.21% | 36.89% | 77.98% | 40.36% | 30.03% | 51.31% | 55.66% | 34.03% |
Income Tax Expense | -1.74M | 2.82M | -433.00K | -28.58M | 1.15M | -826.00K | 21.17M | 9.24M | 10.89M | 46.46M | -15.17M | -221.00K | 0.00 | 3.16M | -157.00K |
Net Income | -116.05M | -133.82M | -121.76M | -79.00M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.40M | 23.31M | 7.90M |
Net Income Ratio | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% | 34.72% |
EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
EPS Diluted | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
Weighted Avg Shares Out | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
Weighted Avg Shares Out (Dil) | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.30M | 19.19M | 9.79M | 2.64M | 2.64M | 14.13M |
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2023 Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
Source: https://incomestatements.info
Category: Stock Reports